Filing Flows › Sutro Biopharma (STRO) › Q3 2025
Sutro Biopharma (STRO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Sutro Biopharma (STRO) reported revenue of $9.7M for the third quarter 2025 (Q3 2025), +14% from a year earlier and -85% from the quarter before. Operating margin was -499.9%, net loss $56.9M (586.6% of revenue).
Sutro Biopharma, Q3 2025: revenue $9.7M (+14% year over year), operating margin -499.9%, net loss $56.9M, operating cash flow −$38.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.7M | -85% | +14% |
| Operating profit | −$48.5M | — | — |
| Net earnings | −$56.9M | — | — |
| Operating cash flow | −$38.2M | — | — |
What changed
Revenue was $9.7M in Q3 2025, up 14% year over year and down 85% from the previous quarter.
Operating costs exceeded revenue by $48.5M, an operating margin of -499.9%. Total costs fell 24% while revenue rose 14%. The quarter ended with a net loss of $56.9M, wider than the previous quarter's $11.5M loss.
Operating cash flow was −$38.2M. Non-cash charges added back $1.9M of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items added $15.2M.
Questions
What was Sutro Biopharma's revenue in the third quarter 2025?
Sutro Biopharma (STRO) reported revenue of $9.7M for the third quarter 2025 (Q3 2025), +14% from a year earlier and -85% from the quarter before.
Was Sutro Biopharma profitable in the third quarter 2025?
Operating loss was $48.5M (-499.9% of revenue) and net loss $56.9M.
Source: Sutro Biopharma 10-Q on SEC EDGAR.